Suchen
Akebia Therapeutics Inc
AKBAZur Watchlist hinzufügen
1.240USD
+0.030+2.48%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
332.19MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Akebia Therapeutics Inc Unternehmen
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Akebia Therapeutics Inc Informationen
BörsenkürzelAKBA
Name des UnternehmensAkebia Therapeutics Inc
IPO-datumMar 20, 2014
CEOButler (John P)
Anzahl der mitarbeiter181
WertpapierartOrdinary Share
GeschäftsjahresendeMar 20
Addresse245 First Street
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02142
Telefon16178712098
Websitehttps://akebia.com/
BörsenkürzelAKBA
IPO-datumMar 20, 2014
CEOButler (John P)
Führungskräfte von Akebia Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.21M
-2.15%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
330.72K
+50.21%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
200.50K
+17.81%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
161.73K
+22.07%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
160.93K
+22.18%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
133.38K
+26.77%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+29.06%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
49.35K
-113.52%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.21M
-2.15%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
330.72K
+50.21%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
200.50K
+17.81%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
161.73K
+22.07%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
160.93K
+22.18%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
133.38K
+26.77%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Akebia Therapeutics Inc?
Die fünf größten Anteilseigner von Akebia Therapeutics Inc sind: Mr. John P. Butler
Wie viele Institutionen halten Anteile an Akebia Therapeutics Inc (AKBA)?
Mit Stand vom 2026Q1 halten 351 Institutionen Anteile an Akebia Therapeutics Inc, mit einem Gesamtmarktwert von etwa 125.97M, was 46.96% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -14935721.00 gestiegen.